Phase II Randomized Controlled Trial of FOLFOXIRI Compared to FOLFOX in First Line Treatment of Chemo-naive Metastatic Colorectal Cancer
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 162
- 试验地点
- 1
- 主要终点
- Progression-free survival after induction and maintenance chemotherapy (PFS1)
研究概览
简要总结
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional chemotherapy with the FOLFOX regimen as first-line treatment of chemo-naive metastatic colorectal cancer patients.
A second primary aim is to evaluate the response rate, safety and tolerability of the chemotherapy of FOLFOXIRI regimen in this patient population.
Patients will be randomized to two therapy groups:
Experimental arm A: Chemotherapy with FOLFOXIRI Standard arm B: Chemotherapy with FOLFOX
详细描述
Survival of patients with metastatic colorectal cancer is correlated with the proportion of patients who receive all the three active drugs , but not with the proportion of patients who receive any second-line therapy. A superior efficacy in PFS,ORR and OS of FOLFOXIRI has been reported with acceptable toxicity. Moreover,evidence suggests that continuous dosing metronomic chemotherapy may be more efficacious than interval-chemotherapy.
Therefore, a way to improve the outcome of metastatic colorectal cancer patients could be to administer a maintenance first-line regimen containing the three active agents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent obtained before any study specific procedures. -Subjects must be able to understand and willing to sign a written informed consent.
- •Male or female subjects ≥ 18 years ≤ 75 years of age
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2.(ECOG PS 0-2 for≥18 years ≤ 65 years of age ，ECOG PS 0-1 for >65 years of age)
- •Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
- •There must be documentation by PET/CT scan, CT scan, MRI, or intraoperative palpation (at the time of resection of the primary colorectal tumor, if applicable) that the patient has evidence of metastases (Histologic confirmation of metastasis is not required.).
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria measured within 4 weeks prior to registration.
- •No previous chemotherapy or target therapy for metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if terminated more than 6 months ago).
- •In case of previous radiotherapy, at least one measurable lesion should be located outside the irradiated field.
- •Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:
- •Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet count ≥ 100 x109/ L, hemoglobin (Hb) ≥9g/ dL.
- •Total bilirubin ≤ 1.5 x the upper limit of normal (ULN).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.
- •Alkaline phosphatase limit ≤ 5x ULN.
- •Amylase and lipase ≤ 1.5 x the ULN.
- •Serum creatinine ≤ 1.5 x the ULN.
- •Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.
排除标准
- •Previous palliative chemotherapy for metastatic disease，previous adjuvant chemotherapy including irinotecan or oxaliplatin within 6 months before random assignment.
- •Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization.
- •Life expectancy > 12 weeks;
- •Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization. Subjects must have recovered from all therapy-related toxicities.
- •Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks before start of study medication.
- •Congestive heart failure ≤ New York Heart Association (NYHA) class
- •Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia
- •Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication.
- •Any evidence of active infection.
- •History of interstitial pneumonitis or pulmonary fibrosis
- •Pregnancy or lactation at the time of study entry.
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency
- •Any illness or medical conditions that are unstable or could jeopardize the safety of the subjects and his/her compliance in the study.
- •Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea
- •Subjects with known allergy to the study drugs or to any of its excipients.
- •Current or recent (within 4 weeks prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
- •Continuous use of immunosuppressive agents (except the use of corticosteroids as anti-emetic prophylaxis/treatment).
研究组 & 干预措施
FOLFOXIRI
FOLFOXIRI
干预措施: FOLFOXIRI (Drug)
FOLFOX
FOLFOX
干预措施: FOLFOX (Drug)
结局指标
主要结局
Progression-free survival after induction and maintenance chemotherapy (PFS1)
时间窗: up to 18 months
Progressions are evaluated every 8 weeks according to WHO criteria and reviewed by an independent panel at the end of follow up (36 months).
次要结局
- toxicity and safety(up to 24 months)
- QLQ (QLQ C30) - scores according to EORTC QLQ-C30 scoring manual (Quality of life)(up to 36 months)
- Progression-free survival after re-introduction of chemotherapy (PFS2)(up to 24 months)
- Response rate during re-introduction of chemotherapy(up to 12 months)
- Overall survival(up to 5 years)
- Translational research(up to 5 years)
- Early tumor shrinkage rate in 8 weeks after induction treatment(8 weeks)
研究者
Yanhong Deng
M.D
Sun Yat-sen University